Severe acute respiratory syndrome-associated coronavirus (SARS-CoV) identified in 2003
infected∼ 8000 people in 26 countries with 800 deaths, which was soon contained and …

The main protease (Mpro) plays a pivotal role in the replication of severe acute respiratory
syndrome coronavirus 2 (SARS-CoV-2) and is considered a highly conserved viral target …

SARS-CoV-2 poses an unprecedented threat to the world as the causative agent of the
COVID-19 pandemic. Among a handful of therapeutics developed for the prevention and …

Inhibitors of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) main
protease (Mpro) such as nirmatrelvir (NTV) and ensitrelvir (ETV) have proven effective in …

The COVID-19 pandemic has emphasized the urgency for effective antiviral therapies
against SARS-CoV-2. Targeting the main protease (3CLpro) of the virus has emerged as a …

The current SARS-CoV-2 pandemic and the likelihood that new coronavirus strains will
emerge in the immediate future point out the urgent need to identify new pan-coronavirus …

Introduction The emergence of the Omicron SARS-CoV-2 variant of concern in late
November 2021 presaged yet another stage of the COVID-19 pandemic. Paxlovid, a co …

In order to address the world-wide health challenge caused by the COVID-19 pandemic, the
3CL protease/SARS-CoV-2 main protease (SARS-CoV-2-Mpro) coded by its nsp5 gene …

This study is aimed to evaluate the safety, tolerability, and pharmacokinetics (PK), as well as
to select an appropriate dosing regimen for the pivotal clinical trial of GST-HG171, an orally …

The COVID-19 pandemic has caused people immense suffering all over the world. Although
the World Health Organization (WHO) has announced the end of the pandemic, the sporadic …